Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) for the reporting period of August 17, 2012, covering events occurring on August 14 and August 15, 2012. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics
The filing outlines the financial terms of a capital raise rather than operational performance metrics like revenue or profit.
- Offering Size: 6,000,000 shares initially, plus 900,000 shares via full over-allotment exercise (Total: 6,900,000 shares).
- Offering Price: $0.40 per share.
- Total Gross Proceeds: $2,760,000.
- Total Net Proceeds: $2,466,800 (after underwriter discounts and estimated expenses).
- Underwriter Compensation: 7.0% discount plus 1.0% expense allowance on gross proceeds.
- Warrants Issued: 300,000 warrants to the underwriter at an exercise price of $0.50 per share (125% of offering price), exercisable after one year with a five-year term.
The filing text does not provide clear values for revenue, operating profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of an Underwriting Agreement with Aegis Capital Corp. and the subsequent full exercise of the over-allotment option. This transaction is expected to increase the company's cash liquidity by approximately $2.47 million upon closing, anticipated on or about August 20, 2012.
Outlook, Risks, and Contingencies
Management Commentary: The offering was made pursuant to an effective Form S-3 registration statement. The company expects the transaction to close subject to customary conditions.
Risks and Contingencies: The Underwriting Agreement requires the company to indemnify the underwriters against certain liabilities under the Securities Act of 1933 or contribute to payments the underwriters may be required to make. The issuance of 300,000 warrants represents a potential future dilution to existing shareholders.
Investor Verification Checklist
- Verify the closing date of the offering (expected August 20, 2012) and confirmation of fund receipt.
- Review the impact of the 300,000 underwriter warrants on future share dilution.
- Confirm the updated total share count post-offering to assess ownership dilution.
- Check subsequent filings for the actual use of the $2.47 million in net proceeds.